Total Payments
$7,617
2023 Payments
$20.81
Companies
11
Transactions
126
Medicare Patients
1,396
Medicare Billing
$176,519
Payment Breakdown by Category
Food & Beverage$2,730 (35.8%)
Research$2,491 (32.7%)
Travel$2,343 (30.8%)
Gifts$53.32 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,730 | 118 | 35.8% |
| Unspecified | $2,491 | 1 | 32.7% |
| Travel and Lodging | $2,343 | 6 | 30.8% |
| Gift | $53.32 | 1 | 0.7% |
Payments by Type
General
$5,126
125 transactions
Research
$2,491
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $5,604 | 16 | $0 (2018) |
| Gilead Sciences, Inc. | $1,338 | 69 | $0 (2023) |
| AbbVie Inc. | $202.63 | 15 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $150.51 | 9 | $0 (2018) |
| Nestle HealthCare Nutrition Inc. | $106.94 | 6 | $0 (2022) |
| Allergan Inc. | $60.34 | 4 | $0 (2018) |
| Braintree Laboratories, Inc. | $53.32 | 1 | $0 (2019) |
| INTERCEPT PHARMACEUTICALS, INC. | $34.43 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $30.27 | 2 | $0 (2018) |
| Shire North American Group Inc | $22.37 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $20.81 | 1 | Gilead Sciences, Inc. ($20.81) |
| 2022 | $119.90 | 5 | Gilead Sciences, Inc. ($82.72) |
| 2021 | $612.37 | 36 | Gilead Sciences, Inc. ($384.62) |
| 2020 | $389.38 | 19 | Gilead Sciences, Inc. ($310.31) |
| 2019 | $317.26 | 19 | Gilead Sciences, Inc. ($263.94) |
| 2018 | $4,162 | 23 | Celgene Corporation ($3,911) |
| 2017 | $1,996 | 23 | Celgene Corporation ($1,693) |
All Payment Transactions
126 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/17/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.81 | General |
| 04/15/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.28 | General |
| 03/11/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.41 | General |
| 02/11/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.03 | General |
| 02/05/2022 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 02/03/2022 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 12/14/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.44 | General |
| 12/10/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $4.78 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/07/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.55 | General |
| 11/05/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.16 | General |
| 10/29/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/26/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.93 | General |
| 10/08/2021 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/01/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.47 | General |
| 09/24/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.36 | General |
| 08/27/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.25 | General |
| 08/21/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/30/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.24 | General |
| 07/16/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: IMMUNOLOGY | ||||||
| 07/16/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $5.08 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/09/2021 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 07/01/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $8.91 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/30/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.13 | General |
| 06/15/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $7.95 | General |
| Category: IMMUNOLOGY | ||||||
| 06/11/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.68 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-10004-UC-001 - A Phase 2, randomized, placebo-controlled, multicenter study to investigate the efficacy and safety of apremilast (CC-10004) for treatment of subjects with active ulcerative colitis | Celgene Corporation | $2,491 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 27 | 29 | $6,530 | $1,624 |
| 2022 | 4 | 67 | 69 | $19,220 | $5,617 |
| 2021 | 11 | 429 | 474 | $146,370 | $54,279 |
| 2020 | 18 | 873 | 980 | $299,490 | $114,998 |
Total Patients
1,396
Total Services
1,552
Medicare Billing
$176,519
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 16 | $3,280 | $1,003 | 30.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $3,250 | $621.48 | 19.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $7,030 | $1,861 | 26.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 20 | 20 | $5,000 | $1,433 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 17 | $3,485 | $1,164 | 33.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 13 | $3,705 | $1,159 | 31.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 69 | 73 | $32,120 | $12,704 | 39.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 77 | 103 | $18,875 | $7,551 | 40.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 70 | 70 | $17,130 | $6,523 | 38.1% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 73 | 74 | $15,970 | $5,518 | 34.6% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 37 | 37 | $14,705 | $4,922 | 33.5% |
| 43246 | Insertion of stomach tube using an endoscope | Facility | 2021 | 27 | 28 | $12,240 | $4,829 | 39.5% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 16 | 17 | $9,325 | $3,528 | 37.8% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 21 | 21 | $7,865 | $2,879 | 36.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 28 | $6,300 | $2,513 | 39.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 12 | 12 | $9,420 | $2,351 | 25.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 11 | 11 | $2,420 | $960.74 | 39.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 160 | 174 | $75,985 | $30,421 | 40.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 141 | 152 | $34,685 | $12,348 | 35.6% |
| 43246 | Insertion of stomach tube using an endoscope | Facility | 2020 | 63 | 67 | $29,375 | $11,870 | 40.4% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 72 | 78 | $30,885 | $10,593 | 34.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 48 | 79 | $17,775 | $7,208 | 40.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 25 | 26 | $14,180 | $5,593 | 39.4% |
| 45378 | Diagnostic examination of large bowel using an endoscope | Facility | 2020 | 39 | 39 | $14,810 | $5,499 | 37.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 42 | 53 | $12,720 | $4,972 | 39.1% |
About Dr. Timothy Simmons, M.D
Dr. Timothy Simmons, M.D is a Specialist healthcare provider based in Long Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124199427.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Timothy Simmons, M.D has received a total of $7,617 in payments from pharmaceutical and medical device companies, with $20.81 received in 2023. These payments were reported across 126 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($2,730).
As a Medicare-enrolled provider, Simmons has provided services to 1,396 Medicare beneficiaries, totaling 1,552 services with total Medicare billing of $176,519. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Long Beach, CA
- Active Since 11/10/2006
- Last Updated 04/09/2020
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1124199427
Products in Payments
- Otezla (Drug) $2,491
- RPC1063 (Drug) $1,693
- Ozanimod (Drug) $1,274
- LINZESS (Drug) $166.18
- ZEPATIER (Drug) $150.51
- ZENPEP (Drug) $106.94
- HUMIRA (Biological) $56.45
- SUPREP BOWEL PREP (Drug) $53.32
- OCALIVA (Drug) $34.43
- MOVANTIK (Drug) $30.27
- Epclusa (Drug) $28.74
- MAVYRET (Drug) $23.38
- GATTEX (Drug) $22.37
- Sucraid (Drug) $14.17
- VIBERZI (Drug) $11.28
- CREON (Drug) $5.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Long Beach
David Morrison, M.d, M.D
Specialist — Payments: $4.9M
Specialist $4.9M
Peter Kurzweil, M.d, M.D
Specialist — Payments: $511,121
Specialist $511,121
Dan Tran, M.d, M.D
Specialist — Payments: $394,164
Specialist $394,164
Dr. David Shavelle, M.d, M.D
Specialist — Payments: $88,220
Specialist $88,220
Philip Yuan, M.d, M.D
Specialist — Payments: $59,461
Specialist $59,461
Dr. Nilesh Vora, M.d, M.D
Specialist — Payments: $18,049
Specialist $18,049